CL2018003072A1 - Anticuerpos anti-basigin humanizados y uso de los mismos. - Google Patents

Anticuerpos anti-basigin humanizados y uso de los mismos.

Info

Publication number
CL2018003072A1
CL2018003072A1 CL2018003072A CL2018003072A CL2018003072A1 CL 2018003072 A1 CL2018003072 A1 CL 2018003072A1 CL 2018003072 A CL2018003072 A CL 2018003072A CL 2018003072 A CL2018003072 A CL 2018003072A CL 2018003072 A1 CL2018003072 A1 CL 2018003072A1
Authority
CL
Chile
Prior art keywords
basigin
antibody
antigen
same
sequence
Prior art date
Application number
CL2018003072A
Other languages
English (en)
Inventor
Zhinan Chen
Ping Zhu
Wan Huang
Zheng Zhang
Yang Zhang
Mengyao Zhang
Huijie Bian
Jianli Jiang
Original Assignee
Fourth Military Medical Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fourth Military Medical Univ filed Critical Fourth Military Medical Univ
Publication of CL2018003072A1 publication Critical patent/CL2018003072A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

LA PRESENTE DIVULGACIÓN PROPORCIONA UN ANTICUERPO ANTI-BASIGIN HUMANIZADO O FRAGMENTO DE UNIÓN A ANTÍGENO DEL MISMO, QUE COMPRENDE UNA REGIÓN VARIABLE DE CADENA PESADA (VH) QUE COMPRENDE UNA SECUENCIA DE AMINOÁCIDOS DE LA SEQ ID NO: 1; OPCIONALMENTE COMPRENDE ADICIONALMENTE UNA REGIÓN VARIABLE DE CADENA LIGERA (VL) QUE COMPRENDE UNA SECUENCIA DE AMINOÁCIDOS DE LA SEQ ID NO: 2. LA PRESENTE DIVULGACIÓN TAMBIÉN PROPORCIONA UNA COMPOSICIÓN QUE COMPRENDE EL ANTICUERPO ANTI-BASIGIN HUMANIZADO O FRAGMENTO DE UNIÓN A ANTÍGENO DEL MISMO, UNA SECUENCIA DE ÁCIDOS NUCLEICOS AISLADA QUE CODIFICA EL ANTICUERPO ANTI-BASIGIN HUMANIZADO O FRAGMENTO DE UNIÓN A ANTÍGENO DEL MISMO, UN VECTOR QUE COMPRENDE EL ÁCIDO NUCLEICO, UNA CÉLULA ANFITRIONA QUE COMPRENDE EL VECTOR, Y USO DEL ANTICUERPO ANTI-BASIGIN HUMANIZADO O FRAGMENTO DE UNIÓN A ANTÍGENO DEL MISMO.
CL2018003072A 2016-04-29 2018-10-29 Anticuerpos anti-basigin humanizados y uso de los mismos. CL2018003072A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610285139.4A CN105820250B (zh) 2016-04-29 2016-04-29 一种抗basigin人源化抗体及其应用

Publications (1)

Publication Number Publication Date
CL2018003072A1 true CL2018003072A1 (es) 2019-05-31

Family

ID=56528099

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003072A CL2018003072A1 (es) 2016-04-29 2018-10-29 Anticuerpos anti-basigin humanizados y uso de los mismos.

Country Status (26)

Country Link
US (1) US20190270809A1 (es)
EP (1) EP3448892A4 (es)
JP (2) JP7099709B2 (es)
KR (1) KR102369118B1 (es)
CN (2) CN105820250B (es)
AU (1) AU2017255888B2 (es)
BR (1) BR112018072140A2 (es)
CA (1) CA3022308A1 (es)
CL (1) CL2018003072A1 (es)
CO (1) CO2018011663A2 (es)
CR (1) CR20180515A (es)
CU (1) CU24556B1 (es)
DO (1) DOP2018000234A (es)
EC (1) ECSP18084153A (es)
IL (1) IL262588A (es)
MA (1) MA44777A (es)
MX (1) MX2018013176A (es)
MY (1) MY196874A (es)
NI (1) NI201800113A (es)
PE (1) PE20190415A1 (es)
PH (1) PH12018502293A1 (es)
RU (1) RU2755150C2 (es)
SG (1) SG11201809473QA (es)
TN (1) TN2018000358A1 (es)
WO (1) WO2017186182A1 (es)
ZA (1) ZA201807132B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105820250B (zh) * 2016-04-29 2019-04-30 中国人民解放军第四军医大学 一种抗basigin人源化抗体及其应用
EP3749373A1 (en) 2018-02-07 2020-12-16 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
CN111690062A (zh) * 2019-03-14 2020-09-22 复旦大学 针对恶性疟PfRh5靶点的全人源单克隆抗体及应用
CN110964119A (zh) * 2019-12-05 2020-04-07 沣潮医药科技（上海）有限公司 抗疟二聚体免疫粘附素、药物组合物和用途
CN111420048B (zh) * 2020-03-11 2023-09-19 中国人民解放军第四军医大学 抗basigin人源化抗体用于制备治疗新型冠状病毒肺炎药物的应用
CN113549152B (zh) * 2021-07-22 2023-06-20 中国人民解放军空军军医大学 一种抗basigin人源化抗体及其应用
CN113925963B (zh) * 2021-10-15 2023-08-11 江苏太平洋美诺克生物药业股份有限公司 一种稳定的包含抗cd147单克隆抗体的药物制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100586960C (zh) * 2006-06-23 2010-02-03 陈志南 HAb18GC2单抗和其轻、重链可变区基因及应用
JP5795833B2 (ja) * 2006-10-27 2015-10-14 エルパス・インコーポレイテッドＬｐａｔｈ， Ｉｎｃ． スフィンゴシン−１−リン酸と結合させるための組成物および方法
US20090104187A1 (en) * 2007-05-21 2009-04-23 Alder Biopharmaceuticals, Inc. Novel Rabbit Antibody Humanization Methods and Humanized Rabbit Antibodies
AU2008305851B2 (en) * 2007-09-28 2014-12-18 Chugai Seiyaku Kabushiki Kaisha Anti-glypican-3 antibody having improved kinetics in plasma
CN101550416B (zh) * 2008-03-18 2012-01-25 陈志南 人源化单抗Hu-ScFv18的轻、重链可变区基因和其编码多肽及其应用
US8007808B2 (en) * 2008-04-04 2011-08-30 The Board Of Trustees Of The Univeristy Of Illinois Composition and method for facilitating the internalization of a therapeutic agent into a cell
EP2303325A4 (en) * 2008-05-23 2012-09-19 Uti Limited Partnership INHIBITION OF EMMPRIN TO TREAT MULTIPLE SCLEROSIS
WO2010087743A2 (en) * 2008-12-30 2010-08-05 Cellartis Ab The use of a protein in stem cell and cancer applications
ES2677564T3 (es) * 2009-06-19 2018-08-03 Inserm (Institut National De La Santé Et De La Recherche Medicale) Método y composición farmacéutica para su uso en el tratamiento de trastornos neurodegenerativos
SI2496698T1 (sl) * 2009-11-03 2019-07-31 City Of Hope Skrajšan epiderimalni receptor faktorja rasti (EGFRt) za selekcijo transduciranih T celic
ES2722300T3 (es) * 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
WO2011112566A2 (en) * 2010-03-11 2011-09-15 Abbott Laboratories Basigin binding proteins
CN104086654B (zh) * 2014-07-04 2016-06-08 中国人民解放军第四军医大学 人源化修饰型抗CD147嵌合抗体HcHAb18及其应用
CN105820250B (zh) * 2016-04-29 2019-04-30 中国人民解放军第四军医大学 一种抗basigin人源化抗体及其应用

Also Published As

Publication number Publication date
IL262588A (en) 2018-12-31
JP7099709B2 (ja) 2022-07-12
AU2017255888A1 (en) 2018-11-22
KR20190020660A (ko) 2019-03-04
AU2017255888B2 (en) 2021-01-07
US20190270809A1 (en) 2019-09-05
MX2018013176A (es) 2019-06-24
ZA201807132B (en) 2021-05-26
BR112018072140A2 (pt) 2019-02-12
MA44777A (fr) 2019-03-06
PH12018502293A1 (en) 2019-07-08
RU2018138053A3 (es) 2020-08-21
TN2018000358A1 (en) 2020-06-15
MY196874A (en) 2023-05-08
CO2018011663A2 (es) 2019-02-08
EP3448892A4 (en) 2019-10-16
CN109476760B (zh) 2021-11-12
CN109476760A (zh) 2019-03-15
SG11201809473QA (en) 2018-11-29
CR20180515A (es) 2019-05-15
RU2755150C2 (ru) 2021-09-13
EP3448892A1 (en) 2019-03-06
CU24556B1 (es) 2021-12-08
CU20180129A7 (es) 2019-06-04
JP2022084832A (ja) 2022-06-07
RU2018138053A (ru) 2020-05-29
JP2019521648A (ja) 2019-08-08
WO2017186182A1 (en) 2017-11-02
CN105820250B (zh) 2019-04-30
CA3022308A1 (en) 2017-11-02
PE20190415A1 (es) 2019-03-19
NI201800113A (es) 2020-01-06
ECSP18084153A (es) 2019-03-29
CN105820250A (zh) 2016-08-03
DOP2018000234A (es) 2018-10-31
KR102369118B1 (ko) 2022-03-03

Similar Documents

Publication Publication Date Title
CL2018003072A1 (es) Anticuerpos anti-basigin humanizados y uso de los mismos.
GT201700162A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
MX2019005116A (es) Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3).
AR107444A1 (es) Composición farmacéutica que comprende constructos de anticuerpo biespecíficos
CO2020004199A2 (es) Anticuerpos específicos cd47/pd-l1
PE20211291A1 (es) Anticuerpos anti-ox40 y metodos de uso
MX2019012793A (es) Agentes anticuerpos dirigidos contra el gen de activación de linfocitos-3 (lag-3) y usos de los mismos.
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
UY37694A (es) Dominios de unión a antígeno humanizados y métodos de uso
PE20181805A1 (es) Composiciones y anticuerpos anti-tim-3
CU24663B1 (es) Dominio de unión a antígeno anti-trbc1, receptor de antígeno quimérico, anticuerpo y acoplador biespecífico de células t que comprenden el mismo
CL2021000517A1 (es) Anticuerpo etiquetado y/o fragmento del mismo que comprende un anticuerpo monoclonal o un fragmento del mismo, que se une específicamente a tau humano; ácido nucleico que lo codifica; vector; célula; método para producir anticuerpo; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003)
CR20170026A (es) Anticuerpos anti-tau humanizados
CO2018002265A2 (es) Anticuerpos anti-cd19 humano humanizados
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
AR101400A1 (es) Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido
PE20190737A1 (es) Anticuerpos anti-cd27
CL2019000119A1 (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123.
CU24568B1 (es) Anticuerpo inhibidor de masp-3
CL2015001895A1 (es) Anticuerpos que se unen al tl1a y sus usos
PE20230381A1 (es) Proteina de union a rgma
CL2017000912A1 (es) Anticuerpos que se unen a ccr6 y sus usos
UY38672A (es) Anticuerpo monoclonal que se une específicamente a gitr
CL2021001104A1 (es) Anticuerpo monoclonal que se une específicamente al antígeno cd20
AR099604A1 (es) Anticuerpos de metaloproteinasa de matriz 9 y sus métodos de uso